|
|
||
Latest News
Stryker Inks Distribution Deal with Etex
Stryker Corp. is helping Etex Corp. broaden its market reach.
The orthopedic manufacturing behemoth has agreed to distribute a pair of bone graft substitute products developed by Etex—Bio MatrX Structure and Bio MatrX Generate. The Bio MatrX Structure product is designed for a complete defect fill while the Bio MatrX Generate is a putty that acts as an osteoconductive scaffold to prompt new bone growth.
Etex describes the products as “synthetic bone graft substitutes that set hard upon implantation” and create a osteo-conductive scaffold that facilitates new bone growth, according to a news release. Both the Bio MatrX Structure and Generate incorporate Etex's nanocrystalline calcium phosphate bone putty.
Bio MatrX Generate is a combination of ETEX's osteoconductive nanocrystalline calcium phosphate and demineralized bone matrix, which is tested for osteoinductive potential by lot, after sterilization, in an in vivo athymic nude rodent muscle pouch model. Both the Bio MatrX Structure and Bio MatrX Generate are approved by the U.S. Food and Drug Administration to be hydrated with saline or blood; they are designed to be used as bone void fillers of the pelvis, extremities and the posterolateral spine, according to the Cambridge, Mass.-based firm.
Brian Ennis, Etex president and CEO, said the deal with Stryker will help his firm broaden its market reach. “Stryker's Spine division possesses the desired distribution and marketing capabilities to increase exposure for ETEX's existing products and emerging technologies. The expansion of our distribution network is a direct reflection of the market interest in our product portfolio. We are pleased that Stryker has selected ETEX as its partner to complement their product offerings in the orthobiologic market segment."
Kalamazoo, Mich.-based Stryker isn't the first company to sell Etex's calcium phosphate bone-grafting technology. In January, Etex signed another non-exclusive distribution agreement for the bone putty with Warsaw, Ind.-based OrthoPediatrics Corp.
In addition to the Bio MatrX products, Etex also manufactures EquivaBone, a moldable, injectable putty made of the nanocrystalline calcium phosphate and demineralized bone matrix used in posterolateral spine fusion procedures; Beta-bsm, an injectable paste; and a moldable putty called Gamma-bsm. The latter two are also designed to create a scaffold to promote new bone growth.
The orthopedic manufacturing behemoth has agreed to distribute a pair of bone graft substitute products developed by Etex—Bio MatrX Structure and Bio MatrX Generate. The Bio MatrX Structure product is designed for a complete defect fill while the Bio MatrX Generate is a putty that acts as an osteoconductive scaffold to prompt new bone growth.
Etex describes the products as “synthetic bone graft substitutes that set hard upon implantation” and create a osteo-conductive scaffold that facilitates new bone growth, according to a news release. Both the Bio MatrX Structure and Generate incorporate Etex's nanocrystalline calcium phosphate bone putty.
Bio MatrX Generate is a combination of ETEX's osteoconductive nanocrystalline calcium phosphate and demineralized bone matrix, which is tested for osteoinductive potential by lot, after sterilization, in an in vivo athymic nude rodent muscle pouch model. Both the Bio MatrX Structure and Bio MatrX Generate are approved by the U.S. Food and Drug Administration to be hydrated with saline or blood; they are designed to be used as bone void fillers of the pelvis, extremities and the posterolateral spine, according to the Cambridge, Mass.-based firm.
Brian Ennis, Etex president and CEO, said the deal with Stryker will help his firm broaden its market reach. “Stryker's Spine division possesses the desired distribution and marketing capabilities to increase exposure for ETEX's existing products and emerging technologies. The expansion of our distribution network is a direct reflection of the market interest in our product portfolio. We are pleased that Stryker has selected ETEX as its partner to complement their product offerings in the orthobiologic market segment."
Kalamazoo, Mich.-based Stryker isn't the first company to sell Etex's calcium phosphate bone-grafting technology. In January, Etex signed another non-exclusive distribution agreement for the bone putty with Warsaw, Ind.-based OrthoPediatrics Corp.
In addition to the Bio MatrX products, Etex also manufactures EquivaBone, a moldable, injectable putty made of the nanocrystalline calcium phosphate and demineralized bone matrix used in posterolateral spine fusion procedures; Beta-bsm, an injectable paste; and a moldable putty called Gamma-bsm. The latter two are also designed to create a scaffold to promote new bone growth.
